Application No.: 09/890,088

Attorney Docket No.: 026073-00020

II. AMENDMENTS TO THE CLAIMS

Claims 1-12. (Canceled)

Claim 13. (Currently Amended) A method for the treatment of a pathology affecting

tissues of an eye selected from the group consisting of: sclera, ciliary bodies, crystalline

lens, retina, optic nerve, vitreous body, and choroidea, comprising:

(1) identifying a subject in need of treatment of the pathology,

(2) topically applying a composition comprising from [[10]] 200 to 500 µg/ml of nerve

growth factor over an ocular surface of the subject, and contacting the tissues with the

nerve growth factor to treat the pathology,

wherein the pathology is selected from the group consisting of: cataract, optic neuritis,

glaucoma, maculopathy, retinitis pigmentosa, myopic retinopathy, macular foramen,

uveitis, vitrectomy, ocular hypotonia, scleromalacia, perforating trauma of the sclera,

and phthysis.

Claim 14. (Previously Presented) The method of claim 13, wherein the

composition comprises the nerve growth factor in a pharmaceutically acceptable

ophthalmic carrier and is in a form selected from the group consisting of solutions,

suspensions, ointments, gels, or creams.

Claim 15. (Previously Presented). The method of claim 13, wherein the composition

is in a form selected from the group consisting of an ocular erodible insert, a polymeric

membrane reservoir system to be placed in the conjunctival sac, or in combination with

a local bandage and a therapeutic contact lens.

Claim 16. (Canceled)

Claim 17. (Canceled)

RPP/440016.1

Application No.: 09/890,088 Attorney Docket No.: 026073-00020

Claim 18. (Previously Presented) The method of claim 14, wherein the composition is in the form of an ophthalmic solution.

Claim 19. (Previously Presented) The method of claim 18, wherein the ophthalmic solution contains from 200-250 µg/ml of nerve growth factor.

Claim 20. (Previously Presented) The method according to claim 13, wherein the nerve growth factor is of murine or human origin, or is a human recombinant nerve growth factor.

Claim 21-32. (Canceled)

Claim 33. (Currently Amended) The method of claim [[25]] <u>13</u>, wherein the pathology is a pathology affecting the optic nerve.

Claim 34. (Curretnly Amended) The method of claim [[25]] 13, wherein the pathology is a pathology affecting the retina.

Claim 35-36. (Canceled)